無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

体細胞変異遺伝子を標的とした自己リンパ球の養子免疫伝達:変異率が低い一般的な上皮性癌、消化管癌、胆管癌、および乳癌における成功

Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers

発行 BCC Research 商品コード 667515
出版日 ページ情報 英文 23 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.58円で換算しております。
Back to Top
体細胞変異遺伝子を標的とした自己リンパ球の養子免疫伝達:変異率が低い一般的な上皮性癌、消化管癌、胆管癌、および乳癌における成功 Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers
出版日: 2018年07月20日 ページ情報: 英文 23 Pages
概要

当レポートでは、いくつかの転移性腫瘍の治療における養子細胞移植 (ACT) の臨床研究・治験状況について概説し、腫瘍浸潤リンパ球 (TIL) 療法の拡張性・互換性についての重要事項を取り上げています。

第1章 体細胞変異遺伝子を標的とした自己リンパ球の養子免疫伝達

  • 主な調査結果
  • 腫瘍浸潤リンパ球 (TIL) :癌治療における新たな・刺激的な時代
  • 養子細胞移植 (ACT) およびTIL療法
    • 進行性転移性乳癌の画期的な管理
    • 胆管癌向けTIL療法における成功した進歩
    • 消化管癌の免疫療法への期待
  • ACTおよびTIL療法の限界
  • ACTおよびTIL療法の限界を克服する
  • 治験ポートフォリオの拡大
  • TIL特許情勢の複雑さ
  • TILの次は何か?
  • 展望・影響

第2章 参考資料

第3章 編集者からの注記

第4章 アナリストの経歴

図表

List of Tables

  • Table 1: Overview of PD-1/PD-L1 inhibitors, Mechanisms of Action, Trial Designations and Approved Companion Diagnostics
  • Table 2: Commonly Used Acronyms Associated with Adoptive Transfer of Autologous TILs Therapy

List of Figures

  • Figure 1: Schematic of Adoptive Cell Transfer (ACT) Therapies
  • Figure 2: Schematic of Tumor-Infiltrating Lymphocytes (TILs) Therapies
  • Figure 3: Number of Clinical Trials Incorporating Tumor-Infiltrating Lymphocytes (TILs) Activity, by Phase and Year, by Study Start Date, 2005-2018*
  • Figure 4: Clinical Pipeline Iovance Biotherapeutics
目次
Product Code: BIO171A

Highlights:

Adoptive Cell Therapies (ACTs) and the infusion of autologous or redirected tumor-specific T-cells have the potential to drastically impact the treatment of a variety of cancers, especially common epithelial cancers. This report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

Report Scope:

The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

Report Includes

  • An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
  • Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
  • A brief examination of the patent landscape
  • Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
  • Coverage of number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
  • Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth

Table of Contents

Chapter 1: Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes

  • Key Findings
  • Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in Cancer Treatments
  • Adoptive Cell Transfer (ACT) and Therapeutic TILs
    • Ground-Breaking Management of Advanced Metastatic Breast Cancer
    • Successful Advances in TILs Therapies for Cholangiocarcinoma
    • Hope for Immunotherapy Treatments of Gastrointestinal Cancers
  • Limitations of ACT and Therapeutic TILs
  • Overcoming the Limitations of ACT and Therapeutic TILs
  • Expanding Clinical Trial Portfolio
  • Complexities of the TILs Patent Landscape
  • What's Next for TILs?
  • Outlook and Implications

Chapter 2: References

Chapter 3: A Note from the Editor

Chapter 4: Analyst Credentials

Back to Top